novo semaglutide alzheimer's A Critical Appraisal of the Evoke and Evoke+ trials for disease Novo Nordisk's Ozempic may reduce
Description
Our findings strongly suggest the answer is yes. Primes recent real-world study found 63% of high-potency GLP-1 (Wegovy or Zepbound) users who started treatment in Q1 2024 are still taking their medication after a year
And most people are sending conflicting signals throughout the day
Learn the facts, risks, and alternatives for weight loss
The real problem seems to be retention
